Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI139835, AI117128)
Received: 3 May 2020
Accepted: 17 August 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: All serum samples used in the current study were from a completed study at the Saint Louis University (SLU) and Hepatitis C Therapeutic Registry and Research Network (TARGET) (ExternalRef removed Identifier: NCT01474811). SLU samples were previously collected for research purpose under the Saint Louis University Institutional Review Board (IRB) protocol SLU10592. Serum samples from the TARGET were provided in a code manner, and decoded for treatment outcomes at the stage of data analysis. No other patient information was obtained from the TARGET. No active patient recruitment was involved in the current study. The entire study protocol was reviewed and approved under the Saint Louis University IRB protocol SLU15565. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
: Not applicable.
: The authors have no conflict of interest to declare with respect to this manuscript.